Biocryst Pharmaceuticals (BCRX) Cost of Revenue (2012 - 2026)

Biocryst Pharmaceuticals (BCRX) has reported Cost of Revenue for 15 consecutive years, with $3.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 37.24% year-over-year to $3.8 million; the trailing twelve-month figure through Jun 2026 stood at $20.9 million (up 25.52% YoY), and the FY2025 full-year result was $19.1 million, up 55.47% from the prior year.
• Cost of Revenue slipped to $3.8 million in Q2 2026 per BCRX's latest filing, from $5.4 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $9.5 million in Q4 2025 and bottomed at $236000.0 in Q1 2022.
• Historically, Cost of Revenue has averaged $2.9 million across 5 years, with a median of $2.3 million in 2022.
• The widest YoY moves for Cost of Revenue: up 499.49% in 2022, down 96.02% in 2022.
• Over 5 years, Cost of Revenue stood at $2.4 million in 2022, then tumbled by 34.66% to $1.6 million in 2023, then surged by 291.39% to $6.1 million in 2024, then surged by 56.25% to $9.5 million in 2025, then slumped by 59.67% to $3.8 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $3.8 million, $5.4 million, and $9.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.